In a recent study, neuroscientists at
the
University of California, Berkeley, report that hormone fluctuations
during a
woman’s menstrual cycle may affect the brain as much as do
substances such as
caffeine, methamphetamines
or the popular attention drug Ritalin.
Scientists
have
known
for decades that working memory (short-term information
processing)
is dependent on the chemical dopamine. In fact, drugs like Ritalin
mimic
dopamine to help people concentrate. Researchers have also had evidence
that in
rats, estrogen seems to trigger a release of dopamine. The new study
from
Berkeley, however, is the first to show that cognition is tied to
estrogen
levels in people—explaining why some women have better or worse
cognitive
abilities at varying points in their menstrual cycles.
The Berkeley team examined 24 healthy
women, some
of whom had naturally high levels of dopamine and some of whom had low
levels,
as indicated by genetic testing. As expected, those with the lower
levels
struggled with complicated working memory tasks, such as repeating a
series of
five numbers in reverse order. When the test was repeated during
ovulation,
however, when estrogen levels are highest (usually 10 to 12 days after
menstruation),
these women fared markedly better, improving their performance by about
10%.
Surprisingly, those with naturally high dopamine levels took a nosedive
in
their ability to do complicated mental tasks at that point in their
cycle.
For
women with the lowest levels—about 25 percent of the general
population—increased dopamine during ovulation will sharpen cognitive
functions, whereas for the 25 percent of women with the highest levels,
ovulation seems to take them beyond a threshold and to impair thinking.
The
remaining half of women fall somewhere in between and were not a part
of the
study.
The
work has broad implications: it may mean that caffeine, which triggers
a
dopamine release, and Ritalin-like drugs are less effective—or even
detrimental—at certain times of the month for some women, when estrogen
is
spiking.
But
the estrogen-dopamine link is showing that this may make women more
vulnerable
to addictions. Dopamine is a neurotransmitter involved in the
perception of
rewards such as food, sex and drugs. There is a growing literature on
female
addiction shows that they are not much like their male counterparts.
The
studies point to new drug treatments for addiction as well as practical
tips
for women who want to quit using.
The Weaker Sex?
Although
scientists
have
been studying drug use in women on a small scale since the
1970s, progress was relatively meager before 1994, when the National
Institutes
of Health mandated that most clinical research include women and
minorities. As
research on gender differences greatly accelerated, investigators
uncovered
hints that girls and women may be more vulnerable to addiction and
substance
abuse than men are. Scientists noticed that women more quickly escalate
to
heavy drug use and more readily succumb to the accompanying social and
physical
damage. Even female rats obsessively self-administer addictive drugs
more
readily than male rodents do.
Reproductive hormones may underlie this
susceptibility. Removing the ovaries of female rats so that the animals
no
longer produce estrogen can diminish their tendency to seek out
stimulants such
as cocaine and amphetamine. In addition, giving estrogen to female rats
whose
ovaries have been removed can shorten the path to addiction. In 2004
neuroscientist Jill Becker of the University of Michigan and her
colleagues
reported that it took six days for ovary-free rats to start repeatedly
helping
themselves to infusions of cocaine—in this setup, by poking their noses
into a
hole. In contrast, rats receiving supplemental estrogen succumbed to
the same
compulsion after just four days.
Researchers
believe
that
estrogen spurs addiction by stimulating the brain’s reward
pathways, enhancing the “high” from drugs. Administering estrogen to
rats that
have had their ovaries removed boosts levels of dopamine.
Hormone High
In female mammals, estrogen does not act
alone,
however. Its hormonal partner, progesterone, appears to oppose
estrogen’s
ability to promote addictive tendencies. In 2006 Becker’s team reported
that
giving both estrogen and progesterone to female rats lacking ovaries
does not
accelerate obsessive cocaine use in the rodents, suggesting that
progesterone
may be an antidote to estrogen’s pleasure-seeking influence.
And
more recent work confirms that women’s response to drugs varies across
the
menstrual cycle, as the relative levels of estrogen and progesterone
naturally
wax and wane. In a 2007 study clinical neurobiologist Suzette Evans and
her
colleagues found that stimulants are far more pleasurable to women
during the
estrogen-dominated ‘follicular phase’ (which occupies the approximately
two
weeks from the onset of a woman’s period until she ovulates) than
during the ‘luteal
phase’ after ovulation, when both estrogen and progesterone are high.
A woman’s perception of other kinds of
rewards—such
as money, food and sex—may also vary during her menstrual cycle. In a
2007
study researchers at the NIH scanned women’s brains using functional
MRI as the
women played slot-machine games. They found that women’s reward
circuitry was
more active when they won jackpots during the estrogen-governed phase
of their
cycles than during the progesterone-infused phase that follows. The ebb
and
flow of female hormones could thus have broad effects on the perception
of
pleasures and incentives, influencing women’s motivation to engage in a
wide
variety of behaviors.
A Smarter Way to Stop
Artificially boosting progesterone
levels in women
tempers the “high” they get from drugs. In a 2006 study Evans’s team
gave 11
female cocaine users progesterone when their bodies’ natural levels of
the
hormone were low. The treated women reported feeling a reduced high as
compared
with the one they got at the same point in their cycles in the absence
of
additional progesterone. (In contrast, progesterone did not influence
the
subjective experience of cocaine smoking in the 10 male addicts they
tested, although
the researchers are not sure why.) If progesterone dampens the pleasure
of
drugs, it might help treat addiction in women—something Evans is
currently
testing in female cocaine addicts.
Short
of a chemical fix, paying attention to the calendar could help women
succeed at
quitting smoking, drinking or using drugs. In a study published in
2008, Sharon
Allen, a family medicine doctor at the University of Minnesota Medical
School,
and her colleagues asked half of 202 female smokers to try to quit
during the
second part of their cycles—when progesterone levels are high—and the
others to
make the attempt earlier in their cycles. The results were stunning:
34 percent
of the women in the first group
had
not smoked 30 days later as compared with
only 14 percent of those
who tried to stop smoking when
progesterone levels
were low. When women smoke
early in their cycle, they get more of a kick from
their nicotine, so it might be harder to quit. In this mix of hormones,
brain
chemicals and desire—as in
many other parts of life—timing may be everything.
References:
Allen
SS, Bade T, Center B, et al. Menstrual
phase
effects
on smoking relapse. Addiction (2008), volume 103,
issue 5,
pages 809-821.
Allen
SS, Bade T, Hatsukami D, et al. Craving, withdrawal, and
smoking urges on days immediately prior to smoking relapse.Nicotine and Tobacco
Research (2008), volume 10, issue 1, pages 35-45.
Anthes
E.
She's Hooked: Allure of Vices Tied to a Woman's Monthly Cycle.
Scientific American Mind (2010), volume 21, issue 2, pages 14-15.
Cools
R, Sheridan M, Jacobs E, D'Esposito M. Impulsive
personality predicts dopamine-dependent changes in frontostriatal
activity
during component processes of working memory.Journal
of Neuroscience (2007), volume
27, issue 20,
pages: 5506-5514.
Evans
SM, Foltin RW. Exogenous
progesterone
attenuates the subjective effects of smoked cocaine in women, but not
in men.
Neuropsychopharmaclogy
(2006), volume 31, issue 3,
pages 659-674.
Evans
SM. The role of estradiol and progesterone in modulating the subjective
effects
of stimulants in humans. Experimental and Clinical Psychopharmacology
(2007),
volume 15, pages 418-426.
Hu M,
Crombag HS, Robinson TE, Becker JB. Biological basis of sex
differences in the propensity to self-administer cocaine. Neuropsycholpharmacology
(2004), volume 29, issue
1, pages 81-85.
Jackson
LR,
Robinson TE, Becker JB. Sex
differences and
hormonal influences on acquisition of cocaine self-administration in
rats.Neuropsychopharmaclogy
(2006),
volume 31, issue 1, pages
129-138.
Vance
E. Is estrogen the new Ritalin? Scientific American Mind (2010),
volume 21, issue 2, page 6.